Gamida Cell (GMDA) Stock Forecast, Price Target & Predictions
GMDA Stock Forecast
Gamida Cell stock forecast is as follows: a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
GMDA Analyst Ratings
According to 2 Wall Street analysts, Gamida Cell's rating consensus is 'Buy'. The analyst rating breakdown for GMDA stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 02, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Apr 26, 2022 | JMP Securities | Buy | Buy | Hold |
Gamida Cell's last stock rating was published by Piper Sandler on Oct 02, 2022. The company gave GMDA a "Overweight" rating, the same as its previous rate.
Gamida Cell Financial Forecast
Gamida Cell Revenue Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Jul 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $1.11M | - | - | - | - |
| Avg Forecast | $5.13M | $4.19M | $3.83M | $3.23M | $1.06M | $2.36M | $165.00K | $212.50K | $200.00K |
| High Forecast | $5.13M | $4.19M | $3.83M | $3.23M | $1.23M | $2.36M | $165.00K | $212.50K | $200.00K |
| Low Forecast | $5.13M | $4.19M | $3.83M | $3.23M | $887.92K | $2.36M | $165.00K | $212.50K | $200.00K |
| # Analysts | - | - | - | 1 | 3 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | 1.04% | - | - | - | - |
Gamida Cell's average Quarter revenue forecast for Mar 24 based on 1 analysts is $3.23M, with a low forecast of $3.23M, and a high forecast of $3.23M. GMDA's average Quarter revenue forecast represents a 190.46% increase compared to the company's last Quarter revenue of $1.11M (Dec 23).
Gamida Cell EBITDA Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Jul 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | 3 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | $-11.14M | - | - | - | $-8.31M |
| Avg Forecast | $3.08M | $2.51M | $2.30M | $1.94M | $638.25K | $1.42M | $99.00K | $127.50K | $-15.46M |
| High Forecast | $3.08M | $2.51M | $2.30M | $1.94M | $738.47K | $1.42M | $99.00K | $127.50K | $-12.37M |
| Low Forecast | $3.08M | $2.51M | $2.30M | $1.94M | $532.75K | $1.42M | $99.00K | $127.50K | $-18.55M |
| Surprise % | - | - | - | - | -17.46% | - | - | - | 0.54% |
undefined analysts predict GMDA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Gamida Cell's previous annual EBITDA (undefined) of $NaN.
Gamida Cell Net Income Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Jul 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | 3 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | $-8.84M | - | - | - | $-10.60M |
| Avg Forecast | $-23.67M | $-22.91M | $-22.14M | $-20.62M | $-23.29M | $-25.58M | $-29.78M | $-47.09M | $-13.90M |
| High Forecast | $-23.67M | $-22.91M | $-22.14M | $-20.62M | $-23.29M | $-25.58M | $-29.78M | $-47.09M | $-11.12M |
| Low Forecast | $-23.67M | $-22.91M | $-22.14M | $-20.62M | $-23.29M | $-25.58M | $-29.78M | $-47.09M | $-16.68M |
| Surprise % | - | - | - | - | 0.38% | - | - | - | 0.76% |
Gamida Cell's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GMDA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Gamida Cell SG&A Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Jul 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | 3 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | $9.89M | - | - | - | $4.46M |
| Avg Forecast | $32.07M | $26.21M | $23.95M | $20.19M | $6.65M | $14.79M | $1.03M | $1.33M | $1.25M |
| High Forecast | $32.07M | $26.21M | $23.95M | $20.19M | $7.70M | $14.79M | $1.03M | $1.33M | $1.25M |
| Low Forecast | $32.07M | $26.21M | $23.95M | $20.19M | $5.55M | $14.79M | $1.03M | $1.33M | $1.25M |
| Surprise % | - | - | - | - | 1.49% | - | - | - | 3.57% |
Gamida Cell's average Quarter SG&A projection for Mar 24 is $20.19M, based on 1 Wall Street analysts, with a range of $20.19M to $20.19M. The forecast indicates a 104.06% rise compared to GMDA last annual SG&A of $9.89M (Dec 23).
Gamida Cell EPS Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Jul 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | 3 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | $-0.04 | - | - | - | $-0.31 |
| Avg Forecast | $-0.15 | $-0.15 | $-0.14 | $-0.14 | $-0.15 | $-0.17 | $-0.20 | $-0.31 | $-0.46 |
| High Forecast | $-0.15 | $-0.15 | $-0.14 | $-0.14 | $-0.15 | $-0.17 | $-0.20 | $-0.31 | $-0.46 |
| Low Forecast | $-0.15 | $-0.15 | $-0.14 | $-0.14 | $-0.15 | $-0.17 | $-0.20 | $-0.31 | $-0.46 |
| Surprise % | - | - | - | - | 0.24% | - | - | - | 0.68% |
According to undefined Wall Street analysts, Gamida Cell's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GMDA previous annual EPS of $NaN (undefined).
Gamida Cell Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| GMDA | Gamida Cell | $0.03 | $7.00 | 23233.33% | Buy |
| LXRX | Lexicon Pharmaceuticals | $1.70 | $10.00 | 488.24% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| IBRX | ImmunityBio | $3.58 | $8.00 | 123.46% | Sell |
| IOVA | Iovance Biotherapeutics | $10.34 | $21.57 | 108.61% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| ARDX | Ardelyx | $6.31 | $8.75 | 38.67% | Buy |
| MCRB | Seres Therapeutics | $1.00 | $1.25 | 25.00% | Buy |
| HOOK | HOOKIPA Pharma | $4.99 | $3.00 | -39.88% | Buy |
GMDA Forecast FAQ
Is Gamida Cell a good buy?
Yes, according to 2 Wall Street analysts, Gamida Cell (GMDA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of GMDA's total ratings.
What are Gamida Cell's analysts' financial forecasts?
GMDA's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $16.37M (high $16.37M, low $16.37M), average EBITDA is $9.82M (high $9.82M, low $9.82M), average net income is $-89.336M (high $-89.336M, low $-89.336M), average SG&A $102.42M (high $102.42M, low $102.42M), and average EPS is $-0.585 (high $-0.585, low $-0.585).
Did the GMDA's actual financial results beat the analysts' financial forecasts?
Based on Gamida Cell's last annual report (Dec 2023), the company's revenue was $1.78M, which missed the average analysts forecast of $3.59M by -50.34%. Apple's EBITDA was $-71.584M, missing the average prediction of $2.16M by -3420.76%. The company's net income was $63M, missing the average estimation of $-78.646M by -180.10%. Apple's SG&A was $44.58M, beating the average forecast of $22.48M by 98.37%. Lastly, the company's EPS was $0.0006, missing the average prediction of $-0.515 by -100.12%. In terms of the last quarterly report (Dec 2023), Gamida Cell's revenue was $1.11M, beating the average analysts' forecast of $1.06M by 4.44%. The company's EBITDA was $-11.142M, missing the average prediction of $638.25K by -1845.71%. Gamida Cell's net income was $-8.841M, missing the average estimation of $-23.289M by -62.04%. The company's SG&A was $9.89M, beating the average forecast of $6.65M by 48.67%. Lastly, the company's EPS was $-0.0364, missing the average prediction of $-0.152 by -76.13%